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Feasibility and Diagnostic Validity of the 
M-3 Checklist: A Brief, Self-Rated Screen 
for Depressive, Bipolar, Anxiety, and Post-
Traumatic Stress Disorders in Primary Care
ABSTRACT
PURPOSE Mood and anxiety disorders are the most common psychiatric conditions 
seen in primary care, yet they remain underdetected and undertreated. Screening 
tools can improve detection, but available instruments are limited by the number 
of disorders assessed. We wanted to assess the feasibility and diagnostic validity of 
the My Mood Monitor (M-3) checklist, a new, 1-page, patient-rated, 27-item tool 
developed to screen for multiple psychiatric disorders in primary care.
METHODS We enrolled a sample of 647 consecutive participants aged 18 years 
and older who were seeking primary care at an academic family medicine clinic 
between July 2007 and February 2008. We used a 2-step scoring procedure to 
make screening more effi cient. The main outcomes measured were the sensitiv-
ity and specifi city of the M-3 for major depression, bipolar disorder, any anxiety 
disorder, and post-traumatic stress disorder (PTSD), a specifi c type of anxiety 
disorder. Using a split sample technique, analysis proceeded from determination 
of optimal screening thresholds to assessment of the psychometric properties of 
the self-report instrument using the determined thresholds. We used the Mini 
International Neuropsychiatric Interview as the diagnostic standard. Feasibility 
was assessed with patient and physician exit questionnaires.
RESULTS The depression module had a sensitivity of 0.84 and a specifi city of 
0.80. The bipolar module had a sensitivity of 0.88, and a specifi city of 0.70. 
The anxiety module had a sensitivity of 0.82 and a specifi city of 0.78, and the 
PTSD module had a sensitivity of 0.88 and a specifi city of 0.76. As a screen for 
any psychiatric disorder, sensitivity was 0.83 and specifi city was 0.76. Patients 
took less than 5 minutes to complete the M-3 in the waiting room, and less than 
1% reported not having time to complete it. Eighty-three percent of clinicians 
reviewed the checklist in 30 or fewer seconds, and 80% thought it was helpful in 
reviewing patients’ emotional health.
CONCLUSIONS The M-3 demonstrates utility as a valid, effi cient, and feasible tool 
for screening multiple common psychiatric illnesses, including bipolar disorder 
and PTSD, in primary care. Its diagnostic accuracy equals that of currently used 
single-disorder screens and has the additional benefi t of being combined into a 
1-page tool. The M-3 potentially can reduce missed psychiatric diagnoses and 
facilitate proper treatment of identifi ed cases.
Ann Fam Med 2010;8:160-169. doi: 10.1370/afm.1092.
INTRODUCTION
P
sychiatric illness is common in primary care settings, where mood 
and anxiety disorders are the 2 psychiatric disorders most frequently 
encountered.1, 2 Although primary care physicians account for most 
mental health visits and write the bulk of antidepressant and antianxiety 
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prescriptions for mood and anxiety disorders in the 
United States,3-5 underrecognition and inadequate 
treatment of these disorders in primary care practices 
remain substantial concerns.5-8 Tools to improve the 
identifi cation and management of these disorders are 
therefore being developed to address this problem.9-11
Despite these efforts, available tools narrowly focus 
on identifying either depressive or anxiety disorders 
and provide little guidance for management. Most 
screening tools target unipolar depression (16.1% 
prevalence),12 and they do not help to differentiate 
unipolar from bipolar spectrum illness. The latter has 
a 3.9% prevalence in community settings,13 but it can 
be as high as 9.8% in primary care.14 A diagnostic error 
can lead to improper treatment of patients with bipolar 
depression; prescribing an antidepressant without a 
mood stabilizer potentially destabilizes the illness and 
increases the risk of a hypomanic, manic, or mixed epi-
sode.15-17 Indeed, bipolar patients seen in primary care 
appear to be at a particularly increased risk of inappro-
priate treatment.18
Also of concern is that depression-screening instru-
ments often do not address anxiety syndromes (28% 
prevalence),12 including generalized anxiety disorder, 
social anxiety disorder, panic disorder, obsessive-
compulsive disorder, and post-traumatic stress disor-
der (PTSD). PTSD, in particular, is not only highly 
prevalent among those returning from service in the 
US Armed Forces,19 but it is also quite common in 
the general primary care population, where it is often 
underrecognized.20 Coexisting anxiety disorders are 
associated with a more treatment-resistant depressive 
course, suggesting the need for more aggressive treat-
ment or earlier referral to a mental health professional. 
Finally, available anxiety screens21 singularly address 
anxiety rather than the full spectrum of mood and 
anxiety disorders.
Given the limitations of currently available assess-
ment instruments, we now report on the feasibility 
and diagnostic validity of the My Mood Monitor 
(M-3) checklist, a new, 1-page, patient-rated, 27-item 
tool that screens for 4 types of psychiatric disorders 
encountered in primary care. Our experience in devel-
oping and testing this instrument, and in determining 
the most appropriate means of scoring it, may provide 
useful information on the methods surrounding such 
instrument development. Specifi cally, this report 
addresses 3 questions:
1. What are the preferred M-3 screening thresholds 
for identifying psychiatric illness in primary care?
2. In a prospective testing of these thresholds, 
what are the psychometric characteristics of the M-3 
checklist?
3. What is the feasibility of completing the M-3 in 
a primary care setting from the patient and the clini-
cian perspectives?
METHODS
In this study, we used a cross-sectional design enroll-
ing a convenience sample of consecutive adult patients 
visiting a primary care clinic. After giving informed 
consent, participants completed a self-report symptom 
checklist in the waiting room. At the end of the clinic 
visits, participants and their physicians completed 
questionnaires assessing the feasibility of the symp-
tom self-report. Within 30 days of the index visit, a 
research assistant administered the Mini International 
Neuropsychiatric Interview22 (MINI) to participating 
patients by telephone. Using a split sample technique, 
analysis proceeded from determining optimal screen-
ing thresholds to assessing psychometric properties of 
the self-report instrument using the determined thresh-
olds and the MINI as the diagnostic standard. 
This study was approved by the University of 
North Carolina Institutional Review Board.
Study Population and Sample
The study population comprised all patients visit-
ing the Family Medicine Clinic at the University of 
North Carolina between July 2007 and February 2008 
who were aged at least 18 years, English speaking, 
and mentally competent to provide informed consent. 
This clinic, staffed by 55 clinicians, saw approximately 
18,000 patients per year, with a mean age of 45.7 
years, 60% of whom were female. Nearly two-thirds of 
clinic patients were white (63%); the remainder identi-
fi ed themselves either as African American (30%) or as 
Native American, Asian, or other (7%).
Instruments
Study Questionnaire
Questions were generated by a group of experienced 
mental health clinicians and researchers and were spe-
cifi cally intended for use in primary care settings. The 
M-3 (Supplemental Figure, http://www.annfam
med.org/cgi/content/full/8/2/160/DC1) is a 23-
item self-report symptom checklist that inquires 
whether during the past 2 weeks the patient expe-
rienced symptoms of major depressive disorder (7 
questions), generalized anxiety disorder (2 questions), 
panic disorder (2 questions), social anxiety disorder 
(1 question), PTSD (4 questions), and obsessive com-
pulsive disorder (3 questions). The M-3 also inquires 
about a lifetime history of symptoms of bipolar spec-
trum disorder (4 questions). At the end of the symptom 
checklist, the M-3 poses 4 functional impairment ques-
tions. Patient responses to each of the 27 questions can 
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range from 0 (“not at all”) to 4 (“most of the time”). The 
wording and grammar of the M-3 place it at a sixth- 
grade reading level. The interactive Web site for the 
M-3 can be found at http://www.mymoodmonitor.com/.
Reference Standard
The Mini International Neuropsychiatric Interview 
(MINI), a reliable and valid diagnostic instrument,22-24 
served as the reference standard to evaluate the per-
formance of the M-3. The MINI is widely used,25,26 
well accepted,27 and validated in general medical 
settings.28,29 It has good concordance with other 
diagnostic measures24 and can be administered by tele-
phone when in-person interviews are not feasible or 
practical.30-37 We used the MINI to identify depressive 
disorders, bipolar spectrum disorders, and anxiety dis-
orders, as categorized in the Analysis section below.
Study Procedures
A research assistant approached consecutive patients 
entering the Family Medicine Center’s waiting area. To 
avoid sampling bias, the assistant approached a maxi-
mum of 3 consecutive patients of each attending clini-
cian. To avoid overrepresentation of participants with 
mental health concerns, potential participants were 
invited to complete a general health survey for their 
clinician’s use in guiding their health care management. 
Before the clinician visit, participants completed the 
M-3 checklist and returned it to the practice nurse, 
who attached the checklist to the top of the chart for 
review by the clinician before entering the examina-
tion room. The clinician was instructed to review the 
checklist with the patient and to use the information 
however he or she wished.
After the appointment ended, the clinician 
answered a brief exit questionnaire regarding the ease 
and usefulness of the M-3. Participants completed a 
similar exit questionnaire surveying its feasibility. We 
collected demographic data using a separate form and 
used record abstraction to obtain missing data.
Experienced master’s level diagnostic interviewers 
blinded to M-3 results administered the MINI, either 
in person immediately after the clinic visit or as soon 
as possible by telephone but within 30 days after the 
index visit. The interviewers assigned fi nal diagnoses 
after reviewing each interview with a psychiatrist 
(B.N.G.) blinded to M-3 results.
Analysis
Categorizing the Diagnoses
MINI diagnoses were sorted into 3 categories: depres-
sive disorder, which includes major depressive disorder 
or dysthymia in the absence of major depression; bipo-
lar disorder (type 1 or type 2), which could include a 
current or past episodes; and anxiety disorders, which 
include generalized anxiety disorder, panic disorder, 
social anxiety disorder, obsessive compulsive disorder, 
agoraphobia, and PTSD. Participants experiencing an 
anxiety disorder were further assessed specifi cally for 
PTSD. Participants lacking an M-3 checklist or MINI 
diagnosis were excluded from the analysis. Each unan-
swered M-3 question was assigned a value of 0.
M-3 Scoring
Appreciating that false-positive fi ndings can increase 
the workload of primary care physicians and lead to 
improper treatment of the patient, and that the Diag-
nostic and Statistical Manual of Mental Disorders38 requires 
functional impairment for diagnosing psychiatric dis-
orders, we used the functional impairment questions of 
the M-3 as a fi rst-stage screen. The remaining checklist 
symptoms were then scored for only those patients 
whose screen was positive for functional impairment. 
This gateway method provided the best balance of 
increasing sensitivity and specifi city while permitting
a quick, visually intuitive method for scoring by hand.
The M-3 gateway method is a 2-step scoring pro-
cedure. First, the 4 lifestyle or functional impairment 
questions (questions 24 through 27) and the suicide 
question (question 5) were scored in the following 
manner. Participants responding negatively to the sui-
cide question and who indicated their symptoms did 
not affect their lifestyle (ie, no single lifestyle question 
scored as “often” or “most of the time,” and no more 
than 1 question scored “sometimes”) were given a score 
of 0, and no further scoring was conducted. For all 
other participants passing through the “gate” and at 
risk for experiencing a psychiatric episode, subscores 
of the 4 diagnostic categories were summed as follows: 
responses of “not at all” and “rarely” were scored as 0; 
“sometimes” as 1; and “often” and “most of the time” as 
2. After collapsing response categories from 5 to 3, a 
sensitivity analysis showed that there was no loss in 
sensitivity or specifi city.
To determine optimal screening threshold cut-points 
for each diagnosis, we calculated the sensitivity and 
specifi city of each score using data obtained from the 
fi rst 80% (n = 525) of the cohort. We then calculated 
the threshold identifi ed by both the Youden index39 
and the (0, 1) method by Holmes.40 The Youden index, 
a commonly used measure of diagnostic effectiveness, 
optimizes and gives equal weight to sensitivity and 
specifi city. The (0, 1) method by Holmes also weighs 
sensitivity and specifi city equally but minimizes the 
distance between the receiver operating characteris-
tics curve and the point (0, 1). These 2 methods are 
especially suitable for determining primary care cut-
points of mental health measures, because they are least 
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dependent on population prevalence.41 For depression, 
anxiety, and PTSD, the Youden index39 and (0, 1) 
method40 resulted in the same optimal cut-point. For 
bipolar disorder, the 2 methods resulted in different 
cut-points, and their midpoint was used for the M-3 
screening threshold (rather than 1 or 3, we chose 2).
After determining the optimal screening thresholds 
for sensitivity and specifi city based on the initial 80% 
of cohort participants, we cross-validated these results 
with data from the remaining 20% (n = 122) of the 
cohort. For each diagnosis, the sensitivity and specifi c-
ity resembled or improved upon those established with 
the original cohort. We therefore report results of this 
gateway method for the combined cohort.
Feasibility
We conducted descriptive analyses of the patient 
and physician exit questionnaire data. These analy-
ses included the proportion of patients who reported 
discussing the M-3 checklist with their physicians, 
the duration of the discussion, and the proportion of 
patients perceiving the checklist as helpful to the clini-
cal discussion. From physician responses to the exit 
questionnaire, we report the proportion who reviewed 
the M-3 form and the average time spent doing so, 
reasons for not reviewing the M-3, and its usefulness in 
clarifying the patient’s emotional state.
RESULTS
A total of 723 patients (54% of all patients approached) 
consented to study participation. Although not sys-
tematically recorded, the most common reasons for 
nonparticipation were disinterest in fi lling out a check-
list and anticipated diffi culty in scheduling a follow-up 
interview. Of the 723 study participants, 15 lacked the 
M-3 form, 59 did not complete the MINI, and 2 were 
missing both, leaving analyzable data for 647. Com-
pared with this cohort, patients with a missing M-3 
screen or MINI were similar with regard to age, race, 
sex, and income level.
MINI interviews were successfully completed within 
14 days of the index visit with 81% (523) of participants 
and within 30 days with 99% (639) of the participants. 
The mean number of days between administration of 
the M-3 and MINI for the full group was 8.8 days (SD 
8.2 days). Because an analysis stratifi ed by whether the 
MINI was administered within 2 weeks or 3 to 4 weeks 
of completion of the M-3 found no difference in study 
results between the 2 periods, we report analyses of 
the results of both periods combined. Excluding the 8 
patients whose MINI interviews were conducted after 
30 days did not affect study results, so the following 
analyses include these 8 patients, also. 
Sample Characteristics
Table 1 displays baseline characteristics by type of psy-
chiatric disorder. The study sample appeared represen-
tative of patients seen in this family medicine practice. 
Relative to the clinic’s general population, participants 
were similar in age, race/ethnicity, and general income 
level; however, they were more likely to be female 
(71% vs 60%, P <.001). Fifty-four of the 55 practicing 
clinic physicians participated in the study, and they 
ranged in experience from second-year family practice 
residents to senior faculty.
MINI Mental Illness Prevalence
With regard to psychiatric diagnoses assigned to study 
participants by the MINI, 22% had a depressive disor-
der (16% had major depressive disorder, while 6% had 
bipolar depression), 9.3% had bipolar spectrum illness, 
28.1% had an anxiety disorder, and 6.3% had PTSD 
(Table 2). Overall, 35% of study participants met MINI 
criteria for at least 1 psychiatric diagnosis. Because all 
105 participants whose scores were positive for the 
MINI depressive disorder diagnoses met MINI crite-
ria for a major depressive disorder and not dysthymia 
alone, these participants are reported as major depres-
sive disorder. Of the 60 participants with a lifetime 
diagnosis of bipolar disorder, 8 currently met criteria 
for mania or hypomania (13%), and 37 were currently 
depressed (62% of participants with bipolar disorder 
and 5.7% of the sample, Figure 1).
Anxiety disorders were the most common psychiat-
ric diagnosis among study participants. The most com-
mon subtype was generalized anxiety disorder (n = 117, 
18.1%), followed by agoraphobia (n = 96, 14.8%), panic 
disorder (n = 73, 11.3%) and social phobia (n = 52, 
8.0%). Forty-one patients (6.3%) had PTSD diagnosed. 
In this sample, obsessive-compulsive disorder was rare 
(n = 21, 3.3%).
Psychiatric comorbidities were common in this 
population (Figure 1). More participants had comor-
bid anxiety and depression (12.1%) than either major 
depression (4.2%) or anxiety (9.1%) alone.
M-3 and the 2-Step Scoring Method
The gateway method served as an effi cient scoring 
strategy. The fi rst-step screen for functional impair-
ment eliminated 349 (53.9%) of 647 participants from 
the scoring process, 38 (10.9%) of whom nevertheless 
met MINI criteria for a psychiatric diagnosis. Twenty-
three (6.6%) of the 349 participants who stopped at 
the functionality gate scored all 0s on the M-3; none 
had a psychiatric diagnosis. Of the 298 participants 
passing through the gate and assessed with the M-3, 
186 (62.4%) had a psychiatric diagnosis. Participants 
who passed through the gate were nearly 6 times more 
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likely to have a psychiatric diagnosis than those who 
did not (62.4% vs 10.9%, P <.001).
Psychometrics of M-3, Specifi c Diagnoses
Table 2 specifi es the screening cut-off score pertinent 
to each diagnosis (eg, a score of 2 or more indicates 
a positive screen for bipolar disorder), and the M-3 
questions specifi c to the diagnosis (eg, bipolar disorder 
questions 20 through 23). When compared with the 
MINI-generated diagnosis, the M-3 depression module 
had a sensitivity of 0.84 (95% confi dence interval [CI], 
0.77-0.89) and a specifi city of 0.80 (95% CI, 0.76-
0.83). For this module, the positive likelihood ratio was 
4.19, indicating that a positive screen was more than 4 
times as likely to come from a patient with a depres-
sive disorder than from one without it. Further, given a 
16% prevalence of depression in our population (or an 
odds of about 1 in 6), a patient with a positive screen 
had a post-test odds for depression of approximately 
4:6, or 40%.
The M-3 bipolar module had a somewhat higher 
sensitivity (0.88; 95% CI, 0.77-0.95) but a lower speci-
fi city (0.70; 95% CI, 0.66-0.74). The anxiety module 
had a sensitivity of 0.82 (95% CI, 0.75-0.87) and a 
specifi city of 0.78 (95% CI, 0.74-0.81), whereas the 
PTSD module had a sensitivity of 0.88 (95% CI, 0.74-
0.96) and a specifi city of 0.76 (95% CI, 0.73-0.80). 
A sensitivity analysis was performed to determine 
whether missing data infl uenced the results. When 
only patients with complete data were included in the 





































































































































































































GED = general equivalency diploma; MINI = Mini International Neuropsychiatric Interview.
a Employment status, marital status, education, and income were not collected on the fi rst 99 participants. For all variables, percentages were calculated for partici-
pants with available data.
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analyses, the results were similar to the results obtained 
with the entire study population.
The sensitivity and specifi city of the M-3 com-
pared favorably with those of existing single-disorder 
screening instruments for depres-
sion, bipolar illness, PTSD, and 
anxiety (Table 3). 
M-3 as a Screening Instrument for 
Any Mood or Anxiety Disorder
Given that the M-3 screens for both 
mood and anxiety disorders, we 
wondered whether a positive screen 
for any of the diagnostic categories 
could help identify any mood or 
anxiety disorder (even if different 
from what the positive screen would 
suggest). Of the 647 participants, 
287 were positive (44%) on the M-3 
checklist (Table 2). For all partici-
pants enrolled, sensitivity was 0.83 
and specifi city 0.76, with a positive 
likelihood ratio of 3.48 and a nega-
tive likelihood ratio of 0.22. Thus, 
as a general screen, the M-3 had a 
positive predictive value of 0.65 and 
a negative predictive value of 0.89 
for any mood or anxiety disorder.
Feasibility
Participant Perspective
The M-3 checklist took less than 
5 minutes to complete, and less than 1% of partici-
pants reported lacking suffi cient time to complete it. 
Approximately 70% of participants reported talking 
to their clinician about mood or feelings; among those 













M-3 subscore cutoff (≥) 5 2 3 2 Any positive screena
Question No. 1-7 20-23 8-19 13-16 1-23
Sensitivity (95% CI) 0.84 (0.77-0.89) 0.88 (0.77-0.95) 0.82 (0.75-0.87) 0.88 (0.74-0.96) 0.83 (0.77-0.88)
Specifi city (95% CI) 0.80 (0.76-0.83) 0.70 (0.66-0.74) 0.78 (0.74-0.81) 0.76 (0.73-0.80) 0.76 (0.72-0.80)
Positive LR (95% CI) 4.19 (3.47-5.06) 2.94 (2.53-3.44) 3.65 (3.05-4.39) 3.69 (3.08-4.44) 3.48 (2.90-4.16)
Negative LR (95% CI) 0.20 (0.14-0.29) 0.17 (0.08-0.33) 0.23 (0.17-0.32) 0.16 (0.07-0.36) 0.22 (0.17-0.30)
Positive M-3 screen, % 34 35 39 28 44
Diagnosed by MINI, % 22 9 28 6 35
























CI = confi dence interval; LR = likelihood ratio; M-3 = My Mood Monitor checklist; MINI = Mini International Neuropsychiatric Interview; PTSD = post-traumatic stress 
disorder.
a If any diagnosis cut-off score was met, the screen was considered positive.
b Number with a positive screen and who have that diagnosis by MINI / total number with a positive screen by M-3.
c Number with a negative screen and who do not have that diagnosis by MINI / total number with a negative screen by M-3.
Figure 1. Summary of 224 participants with a diagnosis by MINI.
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who did, 70% did so for at least 1 minute. Sixty-three 
percent of all participants reported that the M-3 
helped them talk to their doctors about their mood or 
feelings. Among participants assigned a MINI diagno-
sis, 75% stated that the M-3 facilitated talking to their 
clinician about mood or feelings.
Clinician Perspective
Eighty-three percent of clinicians reviewed the check-
list in 30 or fewer seconds. None found the M-3 
too complicated, and 80% thought it was helpful in 
reviewing participants’ emotional health.
DISCUSSION
The M-3 is a valid, effi cient, and feasible 1-page tool 
for screening multiple common psychiatric illnesses 
in primary care and other settings. The psychometric 
properties of the M-3 compare favorably with those of 
currently used single-disorder screening tools (Table 
3), thus permitting the M-3 to function both as a 
screen for specifi c anxiety and mood disorder diagno-
ses, as well as a screen for the presence of any mood or 
anxiety disorder (Table 2). Compared with other multi-
condition screens, the M-3 has the additional benefi t 
of integrating screening for bipolar disorder and PTSD 
while screening for other anxiety and mood disorders.
The extensive psychiatric comorbidity found in 
the primary care population underscores the need for 
clinicians to consider multiple psychiatric disorders 
rather than just depression or anxiety alone. In a study 
similar to ours with 100 patients, a primary care phy-
sician administering only the 9-item Patient Health 
Questionnaire42 (PHQ-9), which has a sensitivity of 
0.88, would correctly identify 14 of the 16 depressed 
patients. The PHQ-9 would not identify the 9 patients 
experiencing anxiety alone, however, and would 
misidentify 5 bipolar depressed 
patients as having a unipolar 
major depressive disorder. Simi-
larly, physicians administering 
the 7-item Generalized Anxiety 
Disorder scale45 (GAD-7) alone 
would capture 7 of 9 patients 
with an anxiety disorder alone 
but would miss approximately 20 
patients with bipolar disorder or 
major depressive disorder. Given 
these diagnostic complexities, 
the M-3 potentially can reduce 
missed and misidentifi ed psy-
chiatric episodes and facilitate 
proper treatment of accurately 
identifi ed disorders. Further, 
the M-3 improves upon existing multiple-disorder 
instruments used in primary care practice by offering 
greater diagnostic specifi city and by explicitly iden-
tifying those at risk for bipolar disorder and PTSD 
rather than identifying general diagnostic clusters or 
general levels of distress.46-50
In this initial study of the psychometric proper-
ties and utility of the M-3, we established preferred 
screening thresholds for specifi c psychiatric diagnoses 
using receiver operating characteristic curve analysis. 
We confi rmed that the M-3 accurately screens for both 
specifi c psychiatric diagnoses (eg, major depressive 
disorder) and the presence of a psychiatric diagnosis in 
general (eg, either a mood or an anxiety disorder). Fur-
thermore, both participants and clinicians found it easy 
to use, quick, and clinically helpful.
The 2-step method of scoring effi ciently truncates 
the scoring process at the fi rst step for most patients 
who report no functional impairment. For those 
reporting some degree of impairment, the second scor-
ing step requires little time, and the clinician benefi ts 
from knowing that the total M-3 score has high pre-
dictive power for identifying psychiatric morbidity. 
Furthermore, if the clinician suspects that the patient is 
experiencing a psychiatric disorder, even though he or 
she denies such impairment, the M-3 data can guide a 
more detailed clinical interview.
As with all screening instruments, the M-3 seeks 
to identify effi ciently those patients at high risk for 1 
or more specifi c psychiatric conditions. Although the 
M-3 increases the likelihood of identifying a patient 
experiencing a psychiatric illness, the M-3 by itself 
is not a defi nitive diagnostic instrument. Indeed, as 
a screening tool, the M-3 screen was more likely to 
identify a risk of psychiatric illness than was confi rmed 
by diagnostic interview. The clinician must fully 
investigate symptoms acknowledged by the patient to 













Sensitivity 0.88 0.73 0.74 0.77
Specifi city 0.88 0.90 0.84 0.82
M-3 
Sensitivity 0.84 0.88 0.88 0.82
Specifi city 0.80 0.70 0.76 0.78
CAPS = Clinician-Administered PTSD Scale; GAD-7 = 7-item Generalized Anxiety Disorder scale; M-3 = My 
Mood Monitor checklist; PHQ-9 = 9-item Patient Health Questionnaire; PTSD = post-traumatic stress disorder.
Note: The sensitivity and specifi city for any diagnosis by the M-3 (depression, bipolar, anxiety, or PTSD) was 
0.83 and 0.76, respectively.
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confi rm their diagnostic implications, including rul-
ing out nonpsychiatric causes, such as physical illness, 
bereavement, or substance abuse. Nevertheless, the 
M-3 can facilitate the clinical assessment by identifying 
symptoms requiring fuller exploration and highlighting 
the patient’s level of impairment.
Our study has several limitations. First, our sam-
pling was conducted in a single family practice with a 
patient population and prevalence of psychiatric diag-
noses that may not be representative of other primary 
care practices. Even so, the prevalences obtained in 
this study for anxiety disorders,21 PTSD,51 and bipolar 
disorder14 resemble those reported in the literature. 
The rate of major depression (16.2%) in our study, 
while higher than that reported for primary care set-
tings in general,52 is consistent with the rate obtained 
in other studies of primary care settings,53 including 
those conducted in low-income primary care set-
tings.54 Furthermore, the demographic characteristics 
of our participants correspond to those reported for 
US adult outpatients in the nationally representative 
samples assessed in the National Ambulatory Medical 
Care Survey.55,56 
As a second study limitation, we note that only 
54% of the patients invited to participate did so, 
thereby raising the possibility of bias in that the partic-
ipants could be either more or less likely to experience 
psychiatric symptoms. This participation rate exceeds 
the 50% criterion used in prior analyses of case-fi nd-
ing instruments57 and is greater than some,43,44 but 
not all,45,46 recruitment rates reported in comparable 
studies validating other screening instruments. Further, 
our number of completed MINI reference standard 
interviews (647) is within the range of those performed 
in similar validation studies (eg, 585 with the PHQ-9,46 
and 965 reported with the GAD-7 scale45).
A fi nal study limitation is that faced by all stud-
ies of screening tools for psychiatric diagnoses, ie, 
the absence of a clear reference standard diagnostic 
test and the related evolving conceptualization of 
whether psychiatric research and clinical practice 
are best served by the current categorical approach 
(eg, normal vs disordered) or a dimensional approach 
(mild-severe) toward diagnoses.58,59 Although the cur-
rent study cannot directly address these issues, the use 
of functional impairment by the M-3 as a necessary 
gateway toward positive screening, as well as its con-
sideration of multiple symptoms, supports its use with 
either approach.
The M-3 demonstrates utility as a valid, effi cient, 
and feasible tool for screening multiple common 
psychiatric illnesses, including bipolar disorder and 
PTSD, in primary care. Its screening accuracy equals 
that of currently used single-disorder screening instru-
ments and has the additional benefi t of combining 
them into a 1-page tool. The M-3 potentially can 
reduce missed psychiatric diagnoses and facilitate 
proper treatment of identifi ed cases. Our subsequent 
primary care research will seek to make M-3 self-rat-
ing and scoring increasingly effi cient, assess its gener-
alizability to other medical populations with varying 
sociodemographic profi les, and investigate whether 
the tool can promote collaborative discussion of men-
tal health issues and more evidence-based manage-
ment of psychiatric illness.
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/8/2/160.
Key words: Mental health; health promotion; disease prevention; mass 
screening; depression; anxiety disorder; bipolar disorder; stress disor-
ders, post-traumatic; primary health care
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